GLP‐1 analogues are widely used as treatment for type 2 diabetes mellitus and obesity, and more recently, a dual‐agonist of GLP‐1 and GIP showed promising effects within this field (Coskun et al., 2018). This evidence concerns the gene GLP1R and obesity disorder.